129-Xe MRI Study of Single Triple Therapy Inhaler Effects in COPD Patients With Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation (NCT07192016)
Mechanistic 129-Xe MRI Study of Single Inhaler FF/UMEC/VI Effects in COPD Patients With Persistent, Moderate-severe Dyspnea and/or Poor Health Status With High or Low Risk of Exacerbation
๐ฉบ Plain-English Summary (8th-Grade Level)
The goal of this study is to study how 12-weeks daily (and optional 48-weeks) single inhaler triple therapy (fluticasone furoate (FF)-an inhaled corticosteroid; umeclidinium (UMEC)-a long-acting muscarinic antagonist; vilanterol (VI)-a long-acting ฮฒ2-adrenergic agonist) works to treat adults with COPD. The investigators will compare the effects of this medication on adults with COPD who are at low risk of a flare-up and adults with COPD who are at high risk of a flare-up. The main questions it aims to answer are: * Does FF/UMEC/VI improve ventilation defect percent as measured on 129-Xenon MRI in adults with moderate-severe COPD * Evaluate the relationships between the ventilation defect percent and lung function test results Participants will: * Take the inhaler FF/UMEC/VI once daily for 12-weeks (optional 48-weeks) * visit Robarts 2 times (with optional 3rd visit) for tests and imaging
Who can join: Review the eligibility criteria below.
Location: Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre โ London, Ontario
Age range: 50 Years to 85 Years
๐งช Interventions in This Study
๐ "Do I Qualify?" โ 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria โ
๐ All Participating Trial Locations (1 Sites)
- Robarts Research Institute; The University of Western Ontario; London Health Sciences Centre โ London, Ontario
๐ Contact the Study Coordinator
Phone: (519) 931-5265
Email: gparraga@uwo.ca
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
๐ฐ Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA ยง 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Chronic Obstructive Pulmonary Disease (COPD)
- Laying the Foundation for Building a Resilient KPNC Community in the Face of Worsening Air Quality Due to Wildfire Smoke โ Pleasanton, California
- A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease โ Birmingham, Alabama
- WearME-Pro Phase II: Remote Use Usability and Longitudinal Validation Study (Patch Form Factor). โ Baltimore, Maryland
- Investigating Senolytic Properties in Pulmonary Rehabilitation and Metformin in COPD Exacerbations โ Durham, North Carolina
- Multi-Center Clean Air Randomized Controlled Trial in COPD โ Birmingham, Alabama
- To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment โ Phoenix, Arizona
Explore by condition: All Chronic Obstructive Pulmonary Disease (COPD) clinical trials
๐ก How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.